Skip to main content
OpenTrials
Completed

NCT Number: NCT06662734

Infantile Versus Adult-type Fibrosarcoma and the Risk of Multiple Primary Malignancies

Fibrosarcoma is a malignant tumor originating from mesenchymal tissues and consists of fibroblasts with various types of collagen production. It represents 10% of musculoskeletal sarcomas and less than 5% of all primary bone tumors. It affects middle-aged patients with the most common location in the femur and 70% long tubular bones. Studies reported that fibrosarcoma patients tend to develop a subsequent primary malignancy, the analysis showed a higher risk of SPMs even a decade following the initial diagnosis of fibrosarcoma.

SPMs affect the long-term survival of patients with soft tissue tumors, and since there are no available studies analyzing the risk of second primary malignancies in different types of fibrosarcomas, especially the infantile and adult-type. Therefore, the purpose of this study was to assess the risk of second primary malignancies following primary fibrosarcoma diagnosis for a better understanding of the nature of this rare neoplasm. The investigators used the Surveillance, Epidemiology and End Results (SEER) database to extract the data and calculate the standardized incidence ratio as Observed/Expected and the Excess risk for second primary malignancies with 95% Confidence Interval. Significance was achieved at 0.05.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Suez Canal University

Ismailia, 41512, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with fibrosarcoma from 2000 to 2021.
  • Sequence 0 or 1.
  • Histological types:

Infantile fibrosarcoma, Fibromyxosarcoma, Periosteal fibrosarcoma, Facial fibrosarcoma, Dermatofibrosarcoma, Central odontogenic fibrosarcoma, Ameloblastic fibrosarcoma

Exclusion criteria

  • Patients with unknown histology type

Treatment and study plan

Primary outcomes

  1. The standardized incidence ratio and excess risk of developing multiple primary malignancies following fibrosarcoma diagnosis

    Time frame: from Jan, 2000 till Dec, 2021

    The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the Excess absolute risk for Multiple primary malignancies for fibrosarcoma patients

  2. The standardized incidence ratio and excess risk of developing second primary malignancies for different subtypes of fibrosarcoma

    Time frame: from Jan, 2000 till Dec, 2021

Secondary outcomes

  1. The standardized incidence ratio and excess risk of multiple primary malignancies in fibrosarcoma patients across different racial groups

    Time frame: from Jan, 2000 till Dec, 2021

  2. The standardized incidence ratio and excess risk of multiple primary malignancies in both males and females in fibrosarcoma patients

    Time frame: from Jan, 2000 till Dec, 2021

Sponsors and collaborators

Lead sponsor

asmaa salama ibrahim

Other

Registry information

Official study title

Infantile Versus Adult-type Fibrosarcoma and the Risk of Multiple Primary Malignancies: a Retrospective Cohort Based on SEER Database

Important dates

Study start
2000
Primary completion
2021
Study completion
2021
First posted
Oct 29, 2024
Registry last updated
Oct 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.